Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia

Abstract

We aimed to verify the beneficial effects of probiotic strain Lactobacillus reuteri 263 (Lr263) on hypolipidemic action in hamsters with hyperlipidemia induced by a 0.2% cholesterol and 10% lard diet (i.e., high-cholesterol diet (HCD)). Male Golden Syrian hamsters were randomly divided into two groups: normal (n = 8), standard diet (control), and experimental (n = 32), a HCD. After a two-week induction followed by a six-week supplementation with Lr263, the 32 hyperlipidemic hamsters were divided into four groups (n = 8 per group) to receive vehicle or Lr263 by oral gavage at 2.1, 4.2, or 10.5 × 109 cells/kg/day for 6 weeks, designated the HCD, 1X, 2X and 5X groups, respectively. The efficacy and safety of Lr263 supplementation were evaluated by lipid profiles of serum, liver and feces and by clinical biochemistry and histopathology. HCD significantly increased serum levels of total cholesterol (TC), triacylglycerol (TG) cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C ratio, hepatic and fetal TC and TG levels, and degree of fatty liver as compared with controls. Lr263 supplementation dose dependently increased serum HDL-C level and decreased serum TC, TG, LDL-C levels, LDL-C/HDL-C ratio, hepatic TC and TG levels, and fecal TG level. In addition, Lr263 supplementation had few subchronic toxic effects. Lr263 could be a potential agent with a hypolipidemic pharmacological effect.

Hypolipidemic Effect of Tomato Juice in Hamsters in High Cholesterol Diet-Induced Hyperlipidemia

“…Hamsters were fed a standard chow diet or an HCD adapted from our previous study [ 29 ]. The standard chow (No.…”

Cholesterol-lowering effects of Bacillus coagulans B37 and Bacillus pumilus B9 strains in a rat animal model

“…To date, several studies have been conducted to elucidate the cholesterol reducing ability of probiotic cultures covering mainly Lactobacillus spp., and also Bifidobacterium spp., Streptococcus spp. etc in the experimental animals (Huang et al, 2015;Song et al, 2015) and human beings as well (Shimizu et al, 2015;Sharma et al, 2016). But most are unstable at room temperature and need to be freeze dried or encapsulated via special processes to remain viable during manufacturing, storage and exposure to stomach acid and bile (Martinez et al, 2015).…”

Mini Review on Therapeutic Profile of Phenoxy Acids and Thier Derivatives

“…Fenofibrate (1) and gemfibrozil (2), clinically available hypolipidemic agents possess phenoxy propionic acid moiety in their structure and found to act as weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-α). Hyperlipidemia, characterized by increased blood cholesterol and triacylglycerol levels is considered as the principal risk factor for several lifethreatening cardiovascular diseases [1]. These drugs are highly effective in treating hyperlipidemia by increasing high-density lipoproteins (HDL) levels.…”